|
Wed, 04/23/2025 - 04:27 |
PrEP HIV Prevention Now Available Directly from Illinois Pharmacists |
IDPH |
|
Sat, 08/10/2024 - 02:21 |
D.C. Dept. of Health, Whitman-Walker launch new effort to promote PrEP |
Whitman-Walker ... |
|
Thu, 08/08/2024 - 21:23 |
Medicare Poised to Add Important HIV Drug to Preventive Service List |
Medicare Rights... |
|
Thu, 08/08/2024 - 16:07 |
CMS clarifies plan requirements in upcoming HIV PrEP coverage in Medicare Part B |
NCPA |
|
Fri, 07/26/2024 - 17:33 |
ViiV must urgently help get more people on lifesaving HIV prevention medicine |
Doctors Without... |
|
Tue, 11/29/2022 - 16:00 |
MSF: ViiV must make groundbreaking HIV prevention injection affordable and available |
Doctors Without... |
|
Fri, 11/25/2022 - 11:26 |
PROVINCE RELEASES DATA ON SEXUALLY TRANSMITTED AND BLOOD-BORNE INFECTIONS |
MFCB |
|
Wed, 11/02/2022 - 09:34 |
Sermo Survey Finds Opportunity to Educate General Care Physicians on PReP to Increase Patient Adoption |
SERMO |
|
Wed, 09/21/2022 - 12:51 |
Researchers Receive $4.2M Grant to Improve PrEP Access and Prevent New HIV Infections |
Montefiore |
|
Mon, 09/19/2022 - 21:05 |
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection |
Merck |
|
Fri, 09/02/2022 - 09:30 |
WHO releases new module of the PrEP implementation tool on integration of STI services |
WHO |
|
Wed, 08/17/2022 - 09:14 |
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care |
Gilead Sciences |
|
Tue, 08/02/2022 - 09:03 |
WHO and UNAIDS support countries to introduce virtual interventions and HIV self-testing |
WHO |
|
Fri, 07/29/2022 - 05:54 |
Health Advocates Say We Cant Fail to Accurately Frame Monkeypox |
IP Accuracy |
|
Thu, 07/28/2022 - 17:25 |
MSF: ViiV must do more to accelerate access to new HIV prevention medicine |
Doctors Without... |
|
Thu, 07/28/2022 - 08:31 |
MSF: Following WHO recommendation, ViiV must do more to accelerate peoples access to new game-changing HIV prevention medicine |
Doctors Without... |
|
Thu, 07/28/2022 - 03:44 |
Zimbabwe is the first county in Africa to announce regulatory approval for long-acting injectable cabotegravir for HIV prevention |
WHO |
|
Wed, 07/27/2022 - 07:32 |
WHO launched new implementation guidance for simplified and differentiated service delivery of pre-exposure prophylaxis (PrEP) |
WHO |
|
Wed, 07/27/2022 - 06:45 |
New US$ 1 price for HIV self-tests |
WHO |
|
Wed, 07/27/2022 - 00:57 |
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir |
Gilead Sciences |
|
Tue, 06/14/2022 - 13:09 |
The United States Agency for International Development and PATH Accelerate Efforts to End AIDS in Vietnam |
PATH |
|
Fri, 05/27/2022 - 06:41 |
ViiVHealthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool |
GlaxoSmithKline |
|
Wed, 05/11/2022 - 19:40 |
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV |
Gilead Sciences |
|
Wed, 05/11/2022 - 11:12 |
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV |
Gilead Sciences |
|
Thu, 03/31/2022 - 15:43 |
Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor |
Gilead Sciences |
